_________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
11th–12th February 2021
Register for the event
Approved in principle
Agenda
Please note the final agenda may be subject to change.
Day 1: Thursday 11 February
| 12:00 – 12:15 | Welcome to Masterclass 2021: Opening address |
|---|---|
| 12:15 – 13:30 | Session 1: Immune Thrombocytopenia (ITP) |
| The American Society of Hematology and International Consensus Guidelines for ITP | |
| Adult ITP registry in the UK – what have we learnt? | |
| 13:30 – 13:45 | Break |
| 13:45 – 14:45 | Session 2: Chronic Myeloid Leukaemia (CML) |
| TARGET-CML study: Data from real-world evidence | |
| The Management of CML in 2021 | |
| 14:45 – 15:00 | Break |
| 15:00 – 16:00 | Session 3: Acute Myeloid Leukaemia (AML) |
| An overview of minimal residual disease in AML | |
| Exploring the clinincal utility of minimal residual disease to support treatment decisions | |
| 16:00 – 16:15 | Break |
| 16:15 – 17:15 | Session 4: Myelofibrosis (MF) |
| The value of early intervention in MF | |
| Difficult scenarios and challenging cases in MF | |
| 17:15 | Day close |
Day 2: Friday 12 February
| 11:45 – 12:00 | Welcome to Masterclass 2021: Day 2 |
|---|---|
| 12:00 – 13:30 | Session 5: Myelodysplastic Syndrome (MDS) and Iron Overload (IOL) |
| Mechanisms of IOL in MDS | |
| Impact of iron in MDS: Defining the problem | |
| IOL monitoring and management in MDS | |
| MDS in the clinic – a case study | |
| 13:30 – 13:45 | Break |
| 13:45 – 14:45 | Session 6: Sickle Cell Disease |
| New service configuration in SCD across the UK | |
| An update on the SCD treatment landscape: A case-based approach | |
| 14:45 – 15:00 | Break |
| 15:00 – 16:30 | Session 7: CAR-T Cell Therapy in the Management of Lymphoma |
| Third-line treatment of diffuse large B-cell lymphoma | |
| CAR-T cell therapy referral – who, when, how? | |
| Long-term outcomes of CAR-T cell therapy | |
| 16:30 – 16:40 | Virtual meeting close |
Novartis’ Haematology Masterclass has historically been a two-day face-to-face meeting that aims to support healthcare professionals with a special interest in haematology to share the latest thinking and trial data within the field. By sharing this critical information, the meeting will help to support the implementation of best clinical practice with a focus on the future of patient care within some of the most challenging haematological disorders.
Due to COVID-19 and the current social distancing measures in the UK, Haematology Masterclass 2021 will be hosted virtually.
The event will run from 11th–12th February 2021.
Heritage
Haematology Masterclass has been running for the past six years and continues to deliver the most up-to-date and thought-provoking data in the field of haematology. Since 2014, the meeting has brought presentations from leading specialists in the UK and globally.
Our promise
Novartis is truly committed to providing world-class education to our UK healthcare professionals. We recognise the value this meeting brings to a vast range of physicians including registrars, nurses, pharmacists and consultants. We hope that you can join us for our next meeting in 2021.
This meeting is funded and organised by Novartis Pharmaceuticals Ltd. and is classed as promotional under the Association of the British Pharmaceutical Industry (ABPI) Code.
The prescribing information for the Novartis brands mentioned during this event will be available at this meeting.